From Phase 3 to Practice: How Clinics Can Prepare for Psilocybin Therapy Now
If you're running a ketamine, TMS, or integrative mental health clinic and wondering what comes next, this piece is for you.
Compass Pathways' COMP360 program has now achieved Phase 3 endpoints in not one, but two pivotal trials. This morning, February 17, 2026, the company announced that COMP006, its second Phase 3 trial, met its primary endpoint with high statistical significance. Combined with the positive COMP005 results from June 2025, COMP360 has now demonstrated consistent, clinically meaningful reductions in treatment-resistant depression across more than 800 dosed participants. Compass has already requested a meeting with the FDA to discuss a rolling NDA submission, with a full filing targeted for Q4 2026.
In clinical terms, this is a data milestone. In cultural terms, it is a bell tolling across the mental health landscape.
Psilocybin is no longer a speculative future. We've reached the point where it's a regulated therapy-in-waiting.
And when FDA approval arrives, it will land in a field already stretched thin — in ketamine clinics, integrative psychiatry practices, and functional medicine centers perhaps unprepared for the complexity of psychedelic care, and in systems still shaped by medication models never designed for eight-hour journeys of consciousness.
If you're running a ketamine, TMS, or integrative mental health clinic and wondering what comes next, this piece is for you.
Every serious clinical leader is about to ask the same question: How do we offer psilocybin therapy safely, ethically, and effectively?
And the answer is not "add another service." It's rebuild the architecture of care.
What Phase 3 Actually Signals
Phase 3 means "we're close.”, and it means the therapy has crossed the threshold from experimental to inevitable.
And the COMP360 data tells us something important about what that threshold looks like in practice. In COMP006, two doses of psilocybin administered just three weeks apart produced a rapid onset of effect — measurable from the day after administration — that was sustained through six weeks. In COMP005, participants who responded maintained that effect through at least six months after just one or two doses. These are not the pharmacokinetics of a daily antidepressant. This is an entirely different model of care.
This is the stage where health systems start watching, regulators begin shaping frameworks, investors shift from curiosity to readiness, and clinics realize they cannot improvise.
Psilocybin-assisted therapy is not a medication you prescribe and monitor in 15-minute follow-ups. It is a multi-hour, deeply immersive intervention that requires specialized screening and intake, extended session infrastructure, therapist-guided preparation and integration, medical oversight, environmental design, cultural fluency with altered states, and ethical and legal rigor.
The Coming Bottleneck
When approval arrives, demand may outpace capacity overnight.
Consider the population: treatment-resistant depression affects millions of Americans who have failed multiple rounds of conventional treatment. The COMP360 trials enrolled participants who had not responded to prior antidepressants. These are patients who have been waiting and who will show up at clinic doors the moment this becomes available.
What follows could easily be a scramble for compliant workflows, unanswered questions about scope and licensure, centers attempting to retrofit psychedelic care into psychiatric models that were never built for it, and a shortage of trained facilitators.
Those who wait for approval to begin preparing will discover that the barrier isn't the drug. It's access to infrastructure.
Genuine psilocybin readiness requires:
New intake logic and clinical screening tools
New consent frameworks built for altered-state interventions
New scheduling systems that accommodate extended sessions
Different staffing models and specialized training
Different physical and group journey spaces
New clinical cultures and not just new protocols
New financial models that reflect the actual cost of this care
The clinics that succeed will be the ones who built carefully, in advance.
Insurance
There's another layer of infrastructure: insurance. Not patient-facing coverage, but the malpractice and professional liability coverage that protects your clinic and your clinicians. Ketamine practitioners operate under existing medical malpractice frameworks because ketamine is Schedule III and Esketamine is FDA-approved. Most standard malpractice policies don't automatically extend to emerging or off-label therapies, and gaps in coverage for psychedelic services are already well documented in Oregon and Colorado. We are partnered with legal advisors and insurance experts who can ensure you're properly covered — not just compliant on paper, but genuinely protected.
What the Next 12–24 Months Actually Look Like
Here is a realistic picture of the runway ahead, so you can plan accordingly.
Now through mid-2026: FDA pre-submission meetings. Compass filing its NDA on a rolling basis. State-level regulatory bodies beginning to draft guidance. This is the window to build your infrastructure before the gate opens.
Late 2026: NDA filing complete. FDA review clock begins. This is typically a 10–12 month process, though Priority Review could shorten it. Expect growing media coverage and patient inquiries to start arriving at your clinic doors regardless of approval status.
2027 (potential approval window): DEA scheduling will follow FDA approval — historically within 90 days. At that point, the clinics with trained staff, compliant facilities, and integrated workflows will be able to move. Everyone else will be 12–18 months behind.
The Centers That Will Win
The COMP360 data also signals something about the kind of care that will be required. Across both trials, between 25–39% of participants on the 25 mg dose achieved clinically meaningful symptom reductions. For those who didn't fully remit after one dose, a second dose provided another meaningful window for recovery with over 40% of that group going on to achieve remission. We know this work isn’t one-size-fits-all medication protocol, and will continued to require a responsive, relationship-based, iterative clinical process.
Center should think about…
Treating consciousness as a clinical domain
Understanding that medicine without context can ultimately wound
Building multidisciplinary teams
Designing for meaning
Respecting the cultural lineage of these therapies
Integrating rigor with reverence
How to Start Building Psilocybin Readiness Now
If you plan to offer psilocybin therapy in the next 12–24 months, preparation begins now, with infrastructure. And we are here to help you build. Our team provides experienced clinicians, advisors (legal, financial), insurance experts, and operation specialists.
The first step is an honest assessment of where you currently stand. Most clinics are further along in some areas than they realize (clinical culture, patient relationships, existing integration practices) and significantly behind in others (physical space, legal frameworks, training infrastructure, insurance).
We’ve built a Psilocybin Readiness Assessment.
The Role of Beyond Consulting
We exists for these moments.
We help modern clinic models, integrative practices, and psychedelic therapy centers transition from interest to implementation. We design the clinical, operational, and experiential architecture required to safely, ethically, and compliantly offer psychedelic-assisted therapy, and we begin that work with foresight, experience, and passion.
We can prepare you to offer psilocybin therapy, and most importantly, we'll prepare you to hold it. Modern clinical models may ask for systems, but this work asks for much, much more.
Ready to understand where your clinic stands? Request a Psilocybin Readiness Assessment.
